• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.480 -0.040 (-2.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,897,785
Open 1.490
Bid (Size) 1.490 (1)
Ask (Size) 1.570 (50)
Prev. Close 1.520
Today's Range 1.440 - 1.520
52wk Range 0.8502 - 2.093
Shares Outstanding 26,289,087
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty
Today 14:45 EDT
As per the amended deal, LAVA shareholders will receive an initial cash payment of $1.04 per share, down from the range of $1.16 to $1.24 initially agreed upon. 
Via Stocktwits
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
Today 11:45 EDT
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire

Performance

YTD
+43.7%
+43.7%
1 Month
-2.0%
-2.0%
3 Month
+5.7%
+5.7%
6 Month
+13.0%
+13.0%
1 Year
-10.3%
-10.3%

More News

Read More
Thursday's after hours session: top gainers and losers
October 02, 2025
Via Chartmill
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From XOMA Royalty Corporation; LAVA Therapeutics
Via GlobeNewswire
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
September 30, 2025
Via Stocktwits
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
September 03, 2025
Via Benzinga
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
August 05, 2025
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
August 04, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
August 04, 2025
From Halper Sadeh LLC
Via Business Wire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
August 04, 2025
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
February 28, 2025
Via Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
February 27, 2025
Via Benzinga
On Wednesday, there are stocks with unusual volume. Let's take a look.
February 26, 2025
Via Chartmill
What's going on in today's session
February 25, 2025
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
February 25, 2025
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
February 25, 2025
Via Chartmill
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
August 20, 2024
Via InvestorPlace
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
June 20, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
June 10, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 21, 2024
Via InvestorPlace
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
May 21, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
May 06, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 20, 2024
Via InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
March 20, 2024
From LAVA Therapeutics N.V.
Via GlobeNewswire

Frequently Asked Questions

Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?
LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?
The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market
What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?
The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.480
When was LAVA Therapeutics N.V. - Ordinary Shares last traded?
The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 10/17/25 04:00 PM ET
What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?
The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 38.91M
How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?
LAVA Therapeutics N.V. - Ordinary Shares has 39M shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap